{
    "code": "10000942",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=10000942",
    "time": "2021-11-05 03:25:47",
    "許可證字號": "衛署菌疫輸字第000942號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "112\/06\/14",
    "發證日期": "102\/06\/14",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA01000094202",
    "中文品名": "賀疾妥注射液420毫克",
    "英文品名": "Perjeta Vial 420mg",
    "適應症": "1.1   轉移性乳癌 (MBC) \r\nPERJETA與Herceptin(trastuzumab)及docetaxel併用於治療轉移後未曾以抗HER2或化學療法治療之HER2陽性轉移性乳癌病患。\r\n1.2   早期乳癌 (EBC)\r\nPERJETA與Herceptin(trastuzumab)和化學治療藥物合併使用於：\r\n•    術前輔助療法適用於HER2陽性，局部晚期、發炎性或早期乳癌(腫瘤直徑大於2 cm或淋巴結陽性) 之病患，作為早期乳癌完整治療處方之一部分。\r\n•    術後輔助治療適用於HER2陽性且具有高復發風險 之早期乳癌病患。\r\n說明 : 根據Aphinity臨床試驗結果，在術後輔助治療中，具有高復發風險之HER2陽性早期乳癌病患定義為其乳癌呈淋巴結陽性。",
    "劑型": "27D注射液劑",
    "包裝": "14毫升小瓶 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "Pertuzumab",
    "限制項目": "",
    "申請商名稱": "1901701100  羅氏大藥廠股份有限公司",
    "申請商地址": "台北市信義區松仁路100號40樓、40樓之1、41樓之1",
    "主製造廠": [
        {
            "": "GERMANY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FCH0257000  F. HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "WURMISWEG, CH-4303 KAISERAUGST, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "包裝"
        },
        {
            "製造廠名稱": "FUS0767000  GENENTECH, INC.",
            "製造廠廠址": "1000 NEW HORIZONS WAY, VACAVILLE, CA 95688, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "主成分(drug substance)製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013003800",
            "成分名稱": "Pertuzumab",
            "含量描述": "",
            "含量": "420.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Perjeta 420mg_開盒照內部-104-09-30(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000942&Seq=003&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "20210713_Perjeta CDS 12.0 Chinese PI_0621-PER-01_450x500mm_排-110-07-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000942&Seq=014&Type=9"
        },
        {
            "title": "5. Proposed FB_TW_000942-1-CTN-01-110-01-14.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000942&Seq=010&Type=8"
        },
        {
            "title": "5. Proposed Label_000942-1-LAB-01-110-01-14.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=10000942&Seq=009&Type=8"
        }
    ]
}